Genmab A/S (GE9) Stock Statistics & Valuation Metrics

Genmab A/S has a market cap or net worth of €15.05B. The enterprise value is €63.39B.

Genmab A/S has 64,238,410 shares outstanding. The number of shares has decreased by -2.65% in one year.

Genmab A/S’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 8.86%.

The current PE Ratio of Genmab A/S is 17.5. Genmab A/S’s PEG ratio is ―.

In the last 12 months, Genmab A/S had revenue of 24.60B and earned 6.37B in profits. Earnings per share was 102.47.

In the last 12 months, operating cash flow was 4.81B and capital expenditures -353.58M, giving a free cash flow of 4.46B billion.

Genmab A/S pays an annual dividend of ―, resulting in a dividend yield of ―

Genmab A/S upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Genmab A/S as a current ratio of 2.02, with Debt / Equity ratio of 95.09%

In the past 12 months, Genmab A/S has paid 1.59B in taxes.

Genmab A/S EV to EBITDA ratio is 17.22, with an EV/FCF ratio of 19.80.

Genmab A/S has €10.91B in cash and marketable securities with €143.00M in debt, giving a net cash position of -€24.45B billion.

Gross margin is 93.61%, with operating margin of 33.60%, and net profit margin of 25.89%.

The average price target for Genmab A/S is €313.23, which is 11.43% higher than the current price. The consensus rating is Moderate Buy